Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ophthalmology Associates

Neither a doctor nor a teaching hospital

Research payments

$352,088

86 payments

Through program year 2025, Ophthalmology Associates is reported as receiving $352,088 in research payments, across 86 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $11,000 1
2024 Research $3,724 3
2023 Research $936 1
2022 Research $23,120 3
2021 Research $139,174 37
2020 Research $101,296 11
2019 Research $72,838 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bausch Health US, LLC $131,372 18 payments
  2. Alcon Research LLC $48,223 15 payments
  3. Ocular Therapeutix, Inc. $38,400 7 payments
  4. Amgen Inc. $30,651 3 payments
  5. Kala Pharmaceuticals, Inc. $30,630 10 payments
  6. Glaukos Corporation $25,083 21 payments
  7. Sight Sciences, Inc. $21,050 1 payment
  8. Perrigo Company plc $11,500 4 payments
  9. Regeneron Pharmaceuticals, Inc. $5,300 1 payment
  10. New World Medical,Inc. $4,480 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $87,400 5 payments
  2. A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) $43,972 13 payments
  3. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $30,630 10 payments
  4. A Randomized, Multi-center, Double-masked, Vehicle-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI (Cyclosporine Ophthalmic Insert) for Intracanalicular Use for the Treatment of Subjects With Dry Eye Disease (DED) $25,560 5 payments
  5. Effect of CyPass implantation with concurrent cataract surgery on the accuracy of intraocular lens calculations in patients with open angle glaucoma $22,575 1 payment
  6. ABP 938 Global Phase 3 Study $22,351 2 payments
  7. Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease $21,050 1 payment
  8. An Observational Multicenter Clinical Study to Provide Additional Long- Term Follow-up Beyond 60 Months for Subjects Implanted with a CyPass Micro-Stent in the COMPASS Trial $14,648 13 payments
  9. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $12,859 15 payments
  10. Bioequivalence study $11,500 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record